Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

NCT00119249 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

74

Enrollment

NIH

Sponsor class

Conditions

Stage III Melanoma
Stage IV Melanoma

Interventions

DRUG: sorafenib tosylate
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)